Paying user area
Try for free
Zoetis Inc. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Zoetis Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Free Cash Flow to The Firm (FCFF)
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1, 2 See details »
- Operating Activities Cash Flow
- The net cash provided by operating activities exhibited a generally positive trend over the five-year period. Beginning at $1,795 million in 2019, it increased to $2,126 million in 2020 and continued to rise slightly to $2,213 million in 2021. However, in 2022, a decline was observed, with net cash decreasing to $1,912 million. This downturn was short-lived as the figure rebounded in 2023, reaching the highest level within the period at $2,353 million. Overall, the operating cash flow increased by approximately 31% from 2019 to 2023.
- Free Cash Flow to the Firm (FCFF)
- Free cash flow to the firm showed a similar pattern to operating cash flow, albeit with a slightly more pronounced fluctuation. FCFF started at $1,552 million in 2019 and increased steadily to $1,898 million in 2020 and $1,959 million in 2021. A notable decline occurred in 2022, with FCFF dropping to $1,535 million, which is the lowest figure for the period except for 2019. The following year, 2023, saw a recovery to $1,878 million. Despite the dip in 2022, FCFF in 2023 was higher than in any year before 2020, indicating overall growth of approximately 21% from 2019 to 2023.
- Comparison and Insights
- Both net cash provided by operating activities and free cash flow to the firm followed a broadly similar trajectory, characterized by steady growth through 2021, a decline in 2022, and a recovery in 2023. The decline in 2022 may suggest a temporary operational or investment-related challenge during that year. The subsequent recovery points to a strong return to cash-generating capacity. The gap between operating cash flow and FCFF narrowed slightly in some years, which may imply changes in capital expenditures or working capital management. Overall, the financial data reflect resilient cash flow performance with evidence of cyclical influences.
Interest Paid, Net of Tax
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
2 2023 Calculation
Cash paid during the period for interest, net of capitalized interest, tax = Cash paid during the period for interest, net of capitalized interest × EITR
= × =
3 2023 Calculation
Capitalized interest expense, tax = Capitalized interest expense × EITR
= × =
The financial data reveals notable trends in the effective income tax rate, cash paid for interest, and capitalized interest expense over the five-year period examined.
- Effective Income Tax Rate (EITR) %
-
The effective income tax rate demonstrated a gradual upward trend from 2019 to 2023. Starting at 16.7% in 2019, the rate increased modestly to 18% in 2020 and further to 18.2% in 2021. A more pronounced rise occurred in 2022, reaching 20.5%, with a slight decline to 20.3% in 2023. Overall, the rate increased by approximately 3.6 percentage points across the period, indicating a steady increase in the company's tax burden or effective tax obligations.
- Cash Paid During the Period for Interest, Net of Capitalized Interest, Net of Tax (US$ in millions)
-
The cash outflows for interest payments, adjusted for capitalized interest and tax effects, showed moderate fluctuations over the five years. Beginning at $206 million in 2019, the figure saw a slight increase to $211 million in 2020, followed by a minor decrease to $207 million in 2021. The amount reduced further to $192 million in 2022 before rising again to $235 million in 2023. This pattern indicates variability in interest costs or financing activities, with the most significant increase observed in the final year.
- Capitalized Interest Expense, Net of Tax (US$ in millions)
-
Capitalized interest expense exhibited a consistent upward trend throughout the period. Starting at $11 million in 2019, the expense increased steadily to $14 million in 2020, $16 million in 2021, and $17 million in 2022. The highest amount was recorded in 2023, at $22 million. This gradual increase suggests expanding capital projects or investments in assets requiring capitalization of interest costs, reflecting growing investment activities over time.
Enterprise Value to FCFF Ratio, Current
Selected Financial Data (US$ in millions) | |
Enterprise value (EV) | |
Free cash flow to the firm (FCFF) | |
Valuation Ratio | |
EV/FCFF | |
Benchmarks | |
EV/FCFF, Competitors1 | |
AbbVie Inc. | |
Amgen Inc. | |
Bristol-Myers Squibb Co. | |
Danaher Corp. | |
Eli Lilly & Co. | |
Gilead Sciences Inc. | |
Johnson & Johnson | |
Merck & Co. Inc. | |
Pfizer Inc. | |
Regeneron Pharmaceuticals Inc. | |
Thermo Fisher Scientific Inc. | |
Vertex Pharmaceuticals Inc. | |
EV/FCFF, Sector | |
Pharmaceuticals, Biotechnology & Life Sciences | |
EV/FCFF, Industry | |
Health Care |
Based on: 10-K (reporting date: 2023-12-31).
1 Click competitor name to see calculations.
If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.
Enterprise Value to FCFF Ratio, Historical
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Enterprise value (EV)1 | ||||||
Free cash flow to the firm (FCFF)2 | ||||||
Valuation Ratio | ||||||
EV/FCFF3 | ||||||
Benchmarks | ||||||
EV/FCFF, Competitors4 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
EV/FCFF, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
EV/FCFF, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
3 2023 Calculation
EV/FCFF = EV ÷ FCFF
= ÷ =
4 Click competitor name to see calculations.
The analyzed data reveals fluctuations in both enterprise value and free cash flow to the firm over the five-year period ending in 2023. The enterprise value exhibited an overall increasing trend from 2019 through 2021, rising from approximately US$73.4 billion to nearly US$96.4 billion. However, this was followed by a notable decline in 2022 to about US$83.98 billion, before a moderate recovery to US$88.54 billion in 2023.
Free cash flow to the firm (FCFF) demonstrated a generally positive trend with some variability. It increased steadily from US$1.55 billion in 2019 to US$1.96 billion in 2021, then decreased to US$1.54 billion in 2022, before rebounding to US$1.88 billion in 2023. This pattern indicates some volatility in cash generation capacity during this period, with a dip corresponding to the decline in enterprise value during the same year.
The EV/FCFF ratio, which measures the valuation of the company relative to its cash generation ability, reflected these changes through fluctuations. The ratio decreased from 47.27 in 2019 to 43.54 in 2020, suggesting improved valuation relative to cash flow. Yet, it rose sharply to 49.22 in 2021 and further increased to 54.71 in 2022, indicating that enterprise value outpaced free cash flow during this period, potentially signaling higher valuation multiples or decreased cash flow efficiency. By 2023, the ratio decreased again to 47.16, signaling a partial correction towards previous valuation levels relative to cash flow.
In summary, the data points to a phase of growth in enterprise value and cash flow up to 2021, followed by a period of decline and recovery, with valuation metrics fluctuating in response to these changes. The interplay between enterprise value and free cash flow suggests periods of relative overvaluation and normalization in the later years.